Skip to main content
. Author manuscript; available in PMC: 2010 Sep 10.
Published in final edited form as: Neuron. 2009 Sep 10;63(5):673–682. doi: 10.1016/j.neuron.2009.07.025

Figure 7. Systemic Dopamine D2-type Receptor Antagonist Eticlopride increases Nicotine-induced Potentiation.

Figure 7

(A) Systemic administration of the D2-type receptor antagonist eticlopride (0.5 mg/kg, i.p., n = 3) alone did not significantly alter evoked transmission from the perforant path (F47,47 = 0.62, P > 0.05).

(B) Eticlopride (0.5 mg/kg, i.p., black circles, n = 6) administered 30 min prior to nicotine (1.0 mg/kg, i.p.) enhanced nicotine-induced potentiation when compared to saline injected 30 min before nicotine (gray circles, n = 11) (groups × time: F43,645= 1.91, P < 0.001).